Biotech IPO Gains Crush AI Listings With Standout 55% Return
Hemab Therapeutics Holdings Inc COAG
$47.55
▲ +0.17%
(+$0.08)
Open
$47.37
Prev Close
$47.47
Day Range
$45.44 – $48.62
52W Range
$23.00 – $52.15
Market Cap
$2.22B
Beta
-2.31
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-05-01 |
| Shares Out. | 46,710,000 |
| Website | ir.hemab.com ↗ |
| Phone | 18004831140 |
About Hemab Therapeutics Holdings Inc
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Hemab Therapeutics Holdings Inc is a publicly traded company under the ticker symbol COAG on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)